Educational research only—not investment advice or a recommendation. Scores and estimates may use delayed, incomplete, restated, or corrected market and filing data. Independently verify information before making an investment decision.
Advanced Biomed Inc. Common Stock
ADVBNASDAQ
Wall Street ScoreUnder review
$3.04USD+$0.31 (+11.36%)
The research page contains a warning that has not been mapped to a supported model interpretation. The company research remains available, but the complete score is withheld until the warning is reviewed.
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Primary reporting period: 2025-06-30 · Research updated Oct 13, 2026. A research update is not a new financial filing.
Who they are
Advanced Biomed Inc. functions as an investment holding company, primarily dedicated to the research and development of microfluidic biochip technologies. Based in Taiwan, the company leverages these innovations to enhance precision oncology, spanning cancer detection, diagnosis, and treatment. Its diverse product portfolio includes a suite of advanced devices: A+Pre: A fully automated system designed for pre-concentrating diluted blood samples.
How they make money
Advanced Biomed Inc. is an investment holding company that operates through its subsidiaries. The company currently has no substantive operations or revenue-generating activities and functions primarily as a holding entity for its subsidiaries in Hong Kong and Taiwan.
Products & services
The company is an investment holding company and does not currently provide commercial products or services.
Brands & revenue mix
No separate brand or brand-level revenue disclosure was confirmed in the reviewed sources. This does not mean the company has no brands.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
Customer categories were not separately identified in the reviewed source set.
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
No supplier relationships were confirmed in the sources reviewed. This does not mean the company has no suppliers.
Risks
The company has no substantive operations or assets and is currently in a development stage with no history of revenue.Source
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
•How long can ADVB fund negative free cash flow using its current cash position before it may need more debt or new shares?
•How is ADVB likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
•What specifically needs to improve for ADVB to reach sustainable profitability?
•What future growth or profitability would be needed to justify ADVB's current valuation?
•What does the current fundamental change risk warning mean for the reliability or interpretation of ADVB's score?
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
Volatility = How violently is it moving?
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Community Sentiment
0 active · 0 total calls
0% Bullish (0) 0% Bearish (0)
No personal call yet on ADVB.
Potential upside factors
+Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
Potential downside factors
−Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Medical - Diagnostics & Research industry.
−The company has no substantive operations or assets and is currently in a development stage with no history of revenue.
−Diluted weighted-average shares increased 25.5% year over year.
−Negative free cash flow may increase the need for outside financing and dilution.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdown
Debt
—
Debt Cost—
Debt Reduction YoY-883.1%
Debt / Equity0.36x
Tap for breakdown →
Revenue
—
Revenue YoY—
Revenue CAGR—
Net Margin—
Tap for breakdown →
Asset
—
Asset Growth YoY46.0%
Liquidation/Share$8.51
Net Assets/MCap1.15x
Tap for breakdown →
Capital
—
Earnings Yield-7.9%
Buyback Yield0.0%
Debt Cost—
Tap for breakdown →
Management
—
ROIC-1.3%
ROE-7.4%
ROA-6.4%
Tap for breakdown →
Moat
—
EPS Growth—
FCF/Share Growth—
Rev/Share Growth—
Tap for breakdown →
Valuation
—
Intrinsic Value—
Value Reference—
MOS—
Tap for breakdown →
Buffett
—
Revenue—
Moat—
Valuation—
Tap for breakdown →
MOS
—
MOS %—
Value Reference—
Deep Discount Reference—
Tap for breakdown →
Financial
—
Interest Coverage—
ROIC-1.3%
FCF Yield-2.1%
Tap for breakdown →
Master
—
Financial—
Valuation—
Debt—
Tap for breakdown →
Resilience
—
Survival Years15.9 yrs
Current Ratio2.09x
FCF Margin—
Tap for breakdown →
Was this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
YesNot yetDismiss
Score Changes
Score changes will appear once more historical records are available.
Price vs. Value
Valuation unavailable
Current Price
$3.04
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Value Reference: —
Deep Discount Reference: —
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Monetary values in USD. Share counts in raw units.
Income StatementBalance SheetCash Flow
AnnualQuarterlyTTM + Annual
All rows
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
Line Item
TTM
2025
2024
2023
2022
2021
Revenue
$0.00
$0.00
$0.00
$0.00
····
····
Cost of Revenue
$3K
$11K
$0.00
$12K
····
····
Gross Profit
-$3K
-$11K
$0.00
-$12K
····
····
Research & Development
$493K
$28K
$880K
$45K
····
····
SG&A Expenses
$573K
$55K
$1.3M
$43K
····
····
Operating Expenses
$1.1M
$83K
$2.5M
$88K
····
····
EBITDA
-$1.0M
-$83K
-$2.1M
-$88K
····
····
Operating Income
-$1.1M
-$94K
-$2.5M
-$100K
····
····
Interest Expense
$112.00
$0.00
$0.00
$0.00
····
····
Income Before Tax
-$673K
-$102K
-$2.8M
-$122K
····
····
Income Tax Expense
$0.00
$0.00
$0.00
$0.00
····
····
Net Income
-$678K
-$102K
-$2.8M
-$122K
····
····
Basic EPS
$-0.21
$-0.09
$-0.08
$-0.11
····
····
Basic Shares
1.28M
1.08M
1.08M
1.08M
····
····
Diluted Shares
1.28M
1.08M
1.08M
1.08M
····
····
Upgrade to Premium for up to 10 annual periods, where available.
Estimated earnings date:A future estimated earnings date is not currently available.
Mar 31, 2026Q3FY2026
Revenue
$0
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.38
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
+281.0%
Cash Change
+1567.0%
Margin Change
Not available
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
Cash position grew
What Weakened
Debt increased
Potential Score Impact
Positive indicators included EPS growth, cash levels. Pressure indicators included debt levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
EPS increased 967.4%. Cash increased 1567.0%. Total debt increased 281.0%.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Government disclosed trading activity is available on the Smart Money directory. Filings may be delayed and may not represent complete current holdings.
Dividend HistoryShare
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Predictions & Historical PerformanceShare
Conservative Projected Values
3 Years
$———.——
Premium
5 Years
$———.——
Premium
10 Years
$———.——
Premium
Conservative Projection Rate
——%
Premium
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.